Close Menu

NEW YORK — BioGx said on Tuesday that it has received CE-IVD marking for its expanded respiratory infection assay.

The automated test is designed to detect RNA specific to influenza A, influenza B, respiratory syncytial virus A, and respiratory syncytial virus B present in nasal wash, pharyngeal swab, and nasopharyngeal swab collections. It runs on Becton Dickinson's PCR-based BD Max platform and covers a greater range of viral stains and specimen types than a previously released test, according to Birmingham, Alabama-based BioGx.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.